newsfilter
← Latest News
GlobeNewswire·

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in